#Ribociclib

[cebozcom]

Adding Ribociclib to Endocrine Therapy Enhances Survival in Early Breast Cancer Patients | CeBoz.com

A study reveals that adding ribociclib to endocrine therapy significantly improves survival outcomes in patients with early-stage breast cancer.

[glcarissa]

I haven't posted for a few months due to major health issues. From March 12, 2023, when I first located the lump in my left breast, to the present, it has been heart wrenching and challenging. I no longer have my father or mother, both have sadly passed away, to help me through this. And I don't want to be a burden on my children. Siblings ... all blood is not necessarily family, which is the saddest part of going through this alone.

After being in remission from ovarian cancer surgery in 2018, I was just diagnosed with stage 4 metastatic breast cancer, that has spread to my bones.

The illness and treatment have drastically impacted my physical and mental health to the point where I have not been fully active for several months. It has taken a toll on me, to say the least. Everything has changed. I am sad to admit, also, that many people have also changed. This is a devastating and horrible disease that no one should have to journey alone. But 'it is what it is' and I must keep fighting, whether with support or on my own.

Below is the link to my gofundme page to help me along my cancer journey. If you are able to donate, thank you in advance. If you are not able to donate, please consider sharing my page. I appreciate you all and hope to live as long as possible with this life-changing illness.

Cancer takes away everything. Each day is a battle, but this is my journey and forward I must go.

Stay safe. Be kind. Be humble. Be human.

Gloria C Swain [May 23, 1956 - ]

[global-online-pharmacy]

Ribociclib Kisqali Medication uses, side effects & Lowest cost

Ribociclib is used in combination with another medication to treat a certain type of hormone receptor– positive (depends on hormones such as estrogen to grow) advanced breast cancer or that has spread to other parts of the body in women who have not experienced menopause (change of life; end of monthly menstrual periods) and in those who are close to or who have already experienced menopause. Ribociclib is also used in combination with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive advanced breast cancer or that has spread to other parts of the body as an initial treatment or in people who have not been treated successfully with other treatments in women who have already experienced menopause.

How should this medicine be used?

Ribociclib comes as a tablet to take by mouth. It is usually taken with or without food once daily in the morning for the first 21 days of a 28-day cycle. Take ribociclib at around the same time every day.

What side effects can this medication cause?

Ribociclib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: diarrhea constipation, stomach pain, headache, hair loss, back pain itching, mouth sores, swelling of the hands, feet, ankles, or lower legs difficulty falling asleep or staying asleep

Above content source:  https://www.911globalmeds.com/info/213-1-Ribociclib-Kisqali-Kryxana-Medication-Patient-Information-In-English.pdf

The guaranteed Lowest Cost of Ribociclib / Kisqali 200 mg @ $34.05 and $6.50 per Tablet Online.

Above Price source:

[kmx77]

Novos Fármacos no Combate ao Câncer de Mama: Medicamentos Inovadores que Transformam Vidas

Novos Fármacos no Combate ao Câncer de Mama: Descubra as Armas Inovadoras que Estão Transformando a Luta Contra Essa Doença Devastadora Imagine um mundo onde o câncer de mama não seja mais uma sentença de vida. Onde novos medicamentos revolucionários est

A batalha contra o câncer de mama está em constante evolução, e graças aos avanços científicos e médicos, novos fármacos têm surgido como poderosas armas na luta contra essa doença devastadora. Neste artigo, vamos explorar alguns dos medicamentos inovadores que têm se mostrado eficazes no tratamento do câncer de mama, oferecendo esperança e melhorando a qualidade de vida das…

[thisisnotreallife]

The Cancer Journals, Part XIV:

How to Help a Loved One (or Stranger!)

This week, I start the final drug for my endocrine therapy cocktail. I found out on Friday that the drug, ribociclib, causes hair loss—and that I can’t eat any grapefruit or pomegranate for the entire time I’m taking it, which we expect to be five years.

So.

So today I made a grapefruit cake, and I��ve been chugging my favorite grapefruit bubbly water while I can.

I plan to get myself a paloma before I’m no longer allowed and have a grapefruit for breakfast each morning until I start the medication, too.

Honestly, I feel compelled to ask a medical professional if I need to wait for the grapefruit to flush out of my system before I start the ribo Rx, I’ve had so much of it…

It’s a good thing it’s not pomegranate season!

The grapefruit & pomegranate moratorium is—unfortunately—a hard and fast no. The fruits have something in them (an enzyme, I believe the oral chemotherapy nurse said) that binds to something in the drug, making it difficult for the body to process it properly and leading to a build-up, which can ultimately cause things like liver toxicity.

I let myself be bummed out for about a day and a half, and then I had to admit that having a zero-tolerance policy on grapefruit and pomegranate for the next five years is better than both liver toxicity and a breast cancer recurrence.

So, we take the ribociclib.

And we look forward to a grapefruit and a pomegranate party in five years.

Anyway, as promised, I wanted to wrap up this chapter of my cancer meander not with a grand statement on having and undergoing treatment for breast cancer, but rather with a more practical piece of writing.

When people get sick, or when people experience a death or similar world-shifting event that shakes their foundation, friends and family are quick to tell the afflicted to let them know how they can help.

It’s a wonderful offer—well-intentioned and usually quite genuine.

But the thing is, people who are struggling aren’t thinking clearly about when to ask for help, or whom to ask, or for what.

They just feel overwhelmed—by the illness or the loss and the way that the world just keeps on turning and the bills show up in the mailbox and the fridge keeps getting empty even though they keep going to the store and getting food over and over again and the laundry and the dishes pile up and they still have to get their work done. And shower, too!

So.

So, I thought I would pull together a list of the ways that Patrick and I were supported by our loved ones since we first shared my diagnosis last summer.

If you’re reading this, you likely show up somewhere in the list below, though I didn’t include specific names.

So, thank you for that. Of course. 🫶🏻

My oldest sister and her family came over for a ½ day just before my first round of chemo and knocked out a massive list of things I’d written up that Patrick and I hadn’t been able to get around to around the house since my diagnosis five weeks earlier.

·      My other sister sent soup and mac and cheese and chocolate chip cookies for Patrick and me to have the weekend after my first round of chemo.

·      My colleagues and boss sent fresh groceries delivered to our home just before round 3 of chemo.

·      Local friends brought us a homemade meal of carnitas just after the first round of chemo.

·      Another friend made our Meal Train site for us, which allowed folks to send donations or sign up to send food.

·      My sister signed us up for a meal kit delivery service that we were able to turn on and off based on our needs.

·      My sister also set up a GoFundMe, which allowed people to donate directly to us. We were able to use these funds on medical costs not covered by health insurance (I was spending probably $200 extra a month on supplements my oncology team wanted me on based on my bloodwork and best practices for cancer patients!) and for takeout when I didn’t know what I wanted to eat until I needed to eat immediately after chemo rounds.

·      My sisters also helped with administrative tasks that I delegated to them when I just couldn’t do it myself and didn’t want to burden Patrick on top of him caring for me and working, both full-time—like when I needed an immediate and highly effective birth control method as soon as possible after my diagnosis so that I didn’t get pregnant before cancer treatment started, and my oldest sister called Planned Parenthood to schedule the appointment on my behalf.

·      My mother-in-law asked her friends—most of whom are strangers to me—to send me birthday cards before my birthday in September. Some of them continued to send them on through the holidays, too. One included a drawing by a little 5-year-old girl who wanted to send her love; it is currently on the fridge (obviously).

·      My boss sent a seatbelt pillow for the car before my port surgery, before I even realized I’d need it.

·      A friend sent a Tupperware of homemade cookies and a book of poems along with a sweet card that I have framed.  

·      Another friend sent me a care package before my first chemo round and included items that showed she had done research on what might be helpful for a breast cancer patient, like scar cream and wooden utensils in case metal ones tasted gross post-chemo. So thoughtful!

·      Another friend whom I got to see just after my port surgery gave me a little totem that we call Whimsy Frog, who traveled with me to every chemo round I had to go through.

·      My sister brought me rocks she gathered and polished from shorelines and riverbanks around the Pacific Northwest whenever she visited, and I carried them with me in my pockets and have them placed around my house, for luck.

·      A friend sent the most beautiful and healing care package, filled with the crystal that I took with me to each round of radiation, a necklace she had worn herself through many trials she walked through, and a clear glass frog that now sits in our living room.

·      Another friend sent a cozy scarf and a pack of socks with a cat on them and some tea and sweet little bookmarks to cheer me up and keep me comfortable after my last round of chemo.  

·      Another friend who was diagnosed with the same kind of breast cancer five years ago sent me a sweet coffee mug and a cozy blanket and some “Fuck cancer” cat socks.

·      The mother of a friend of ours from graduate school whom we lived with in Seattle a decade ago sent “comfort pillows” specifically designed by a breast cancer survivor she knows who runs a nonprofit providing support for breast cancer survivors and patients in the western Massachusetts area, along with several other sweet items.

·      My sister found and sent the most perfect post-mastectomy support kit that included pillows and drainage bags and other sweet and thoughtful items that made the days following my mastectomy much, much easier.

·      One of my mother-in-law’s friends, also a breast cancer survivor, sent a hand-crocheted prayer shawl and two hats she made for me, along with a book of letters written to women with breast cancer that she said brought her much comfort during her own cancer meander. We’ve never met, but she was so caring and thoughtful.

·      Another friend sent me an email that meant so much I printed it off and stuck it above my desk so that I would see it every day.

·      My oldest niece watched TikTok and YouTube videos so she would be able to help me put on my wigs. She also bought me some of the cutest hats I’ve ever seen.

·      Anonymous little treats also came in the mail from time to time, from “Suck it, Cancer!” chapsticks that I have stashed all around the house for use to a 2lb bag of coffee beans.

·      I received many beautiful flowers deliveries from friends and family after diagnosis, following my first chemo and my last chemo and in-between rounds “just because,” and post-surgery. Flowers were always, always appreciated.

·      My sister sent a basket of living plants after my mastectomy, and it felt so wonderful to come home to alive things.

·      Online support in the form of likes and comments was always also so appreciated. It might sound cheesy, I know, but each one meant a lot to me and each one still does.  

·      One of my sisters came to stay with us a few days after my mastectomy. It was nice for Patrick to not have to stop what he was doing every time I needed a glass of water or a snack, since I could ask my sister for her help, too.

·      When my sister visited after my mastectomy, her best friend drove down from Seattle and stayed here for a couple nights, too. She had done some research on the best foods for post-surgical recovery and made a protein-packed loaf of banana bread and a protein-packed chicken sausage and tortellini and vegetable soup that we survived on for a few days. Before she left, she and my sister cleaned our house for us and did our laundry. What?! If you don’t live nearby and can’t travel to help a loved one in person, if you can afford to set up a laundry service for pick up and drop off or a cleaning service to come regularly to take care of basic housekeeping and occasional deep cleaning needs, those services would be incredibly helpful during a time of need.

I’m sure that I’ve forgotten something. We received so many wonderful gifts and acts of kindness and support that I couldn’t possibly list every one of the wonderful things that friends and family did for us.

What helped Patrick and I the most over the last six months was people taking the time to send a message of support or to do some research to figure out how they could help in other ways. It was people following through on those offers for help in tangible ways—and in intangible ways, too. It was not having to say “we need some help,” because—of course, absolutely—anyone dealing with cancer does. Always.

In any case, the point is, I’m compiling all of these acts of love and care in the hopes that the next time one of your loved ones receives a scary diagnosis or loses a loved one or otherwise needs your love and support, you don’t need to ask how to help.

I hope that, instead, you can show up—unannounced or with due warning, depending on your relationship—with a homemade, nutritionally-appropriate meal and do a load of laundry.

Or send a bouquet of flowers and a pair of cozy socks.

Or a message of love and encouragement or commiseration that your friend or sister or nephew can hold in their heart when things feel especially tough.

[drcare4u]

Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer

Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) with endocrine therapy but without chemotherapy has been shown to potentially be an effective treatment for patients with HER2-positive and hormone receptor (HR)-positive metastatic breast cancer. Furthermore, the addition of Kisqali (ribociclib) might improve patient outcomes even more. These findings come from the second interim…

[schoje]

Uma nova resolução normativa da Agência Nacional de Saúde Suplementar (ANS), publicada hoje (2) no Diário Oficial da União, promoveu uma ampla atualização nos procedimentos e eventos que devem ter cobertura garantida por planos de saúde privados. Novos exames e tratamentos passaram a fazer parte da lista obrigatória de assistência, que deverá ser observada a partir de abril. Ao todo, foram adicionadas 69 coberturas, sendo 50 relativas a medicamentos e 19 referentes a exames, terapias e cirurgias indicadas no tratamento de enfermidades do coração, intestino, coluna, pulmão e mama, entre outras.  Entre os remédios, passam a integrar a lista obrigatória de assistência 17 imunobiológicos que poderão ser usados para tratar doenças inflamatórias, crônicas e autoimunes, como psoríase, asma e esclerose múltipla. Outros 19 são antineoplásicos orais indicados no enfrentamento de diversos tipos de câncer. Mulheres com tumor na mama em estágio avançado, por exemplo, poderão contar com a cobertura do Abemaciclibe, Ribociclibe e Palbociclibe. Outra droga incluída é o Osimertinibe, que tem sido apontado em estudos como responsável por aumentar a sobrevida de pacientes com câncer de pulmão metástico. A lista traz ainda novas opções para tratar leucemias, melanomas, mielomas e tumores de fígado, rim e próstata. Em relação às cirurgias, terão coberturas novas intervenções para tratar hérnia de disco lombar e deformidade na mandíbula, além de problemas na coluna cervical e no coração. Os exames e terapias incluídos permitirão diagnósticos e tratamentos de tuberculose, inflamação intestinal, leucemia mielóide, cânceres de pulmão e de mama, entre outras doenças. Consultas com enfermeiro obstetra ou obstetriz também têm agora assistência garantida. Validade As mudanças foram aprovadas em reunião na última quarta-feira (24). Elas valem para todos os planos contratados a partir de 1999. Também se aplicam aos que foram contratados antes dessa data que tiverem sido adaptados conforme a lei federal 9.656/1998, conhecida como Lei dos Planos de Saúde. Segundo nota divulgada pela ANS, a elaboração da nova resolução normativa se deu a partir de um processo transparente e de uma análise robusta, que contou com diversas etapas de discussões técnicas e com ampla participação da sociedade, que enviou 30.658 contribuições durante consulta pública aberta entre outubro e novembro do ano passado.  "Pela primeira vez no processo de revisão do rol foram utilizados, de modo sistematizado, dados de saúde e informações financeiras para a análise crítica das avaliações econômicas e para as estimativas de impacto orçamentário de cada tecnologia", diz o texto. A atualização, segundo a ANS, levou em conta critérios variados como os benefícios clínicos comprovados, o alinhamento às políticas nacionais de saúde e a relação entre custo e efetividade. Os procedimentos incorporados foram aqueles em que os ganhos coletivos e os resultados clínicos foram considerados os mais relevantes para o conjunto dos pacientes.

[bhushans]

Unveiling the Power of Data: Global Breast Cancer Drug Market

The global breast cancer drug market is set for steady growth over the next decade. Valued at USD 10,733.1 million in 2023, the market is projected to reach approximately USD 12,012.1 million by 2033, with a compound annual growth rate (CAGR) of 1.1% during the forecast period.

The increasing prevalence of breast cancer and the continuous evolution of novel therapies are key factors driving this market expansion. Early detection remains crucial for the effective management and treatment of breast cancer, further bolstering the demand for advanced drug therapies.

Your Insightful Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-1246

One of the most prevalent malignancies affecting women globally, breast cancer has a significant effect on public health. Improving patient outcomes and lowering the disease’s mortality rates depend on the creation of novel treatments as well as improvements in early detection techniques.

Breast cancer is caused by a multitude of factors, such as genetic mutations (abnormal variations), age, inheritance, lifestyle, and heredity. Researchers are looking into novel imaging modalities to assess anomalies during the early stages of the disease and trying to determine the impact of genetic changes on breast cancer.

Key Takeaways:

The global breast cancer drug market is projected to reach US$12,012.1 million by 2033, reflecting a rise from US$10,733.1 million in 2023.

This growth is expected at a moderate compound annual growth rate (CAGR) of 1.1% throughout the forecast period.

The rising prevalence of breast cancer and the development of novel therapies are key drivers for market expansion.

Competitive Landscape:

In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.

In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.

Key Companies Profiled:

F. Hoffmann-La Roche Ltd

Pfizer Inc.

AstraZeneca

Novartis International AG

Achieve Life Science

Bristol-Myers Squibb

Eisai Co. Ltd

AbbVie

Eli Lilly & Company

Celgene Corporation

Merck & Co.

Amgen Plc.

Celldex Therapeutics

Biocon Genzyme Corporation

Key Segments Covered in the Breast Cancer Drug Industry Analysis:

By Drug Class:

SERM (Selective Estrogen-Receptor Modulators)-based

Aromatase Inhibitors-based

Biologic Response Modifiers-based

Other Hormonal Therapies-based

By Distribution Channel:

Hospital Pharmacies

Pharmacies

Drug Stores

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

[edenmartinez]

A 45-year-old premenopausal woman with underlying inflammatory bowel disease underwent lumpectomy and sentinel node biopsy, with surgical pathology demonstrating a 3.5-cm invasive ductal carcinoma, grade 3, with 2 of 3 sampled nodes positive. Her biomarkers are estrogen receptor 80%, progesterone receptor 30%, and HER2 negative (immunohistochemistry [IHC] 0). Germline BRCA testing is negative. She receives adjuvant chemotherapy with dose‑dense AC-T (doxorubicin and cyclophosphamide followed by paclitaxel) followed by radiation therapy.

In addition to ovarian suppression, which of the following adjuvant therapies would you recommend for this patient?

A

13.0%

Aromatase inhibitor (AI) only

B

51.9%

AI + abemaciclib 

C

5.6%

AI + olaparib

D

29.6%

AI + ribociclib

 Your Answer: B

Correct Answer: D

Adjuvant endocrine therapy plus a CDK4/6 inhibitor is recommended for this patient because her nodal positivity and high disease grade increase her risk of recurrence. Phase III trials have shown that adding abemaciclib or ribociclib to adjuvant endocrine therapy significantly prolongs invasive disease–free survival (iDFS) in patients with high-risk HR-positive/HER2-negative EBC. She is eligible for abemaciclib per the label and ribociclib per NATALEE eligibility criteria, but ribociclib would be preferred in a patient with an underlying bowel comorbidity because diarrhea is more common with abemaciclib (occurred in 83.5% of monarchE participants) than with ribociclib (occurred in 14.5% of NATALEE participants). She is ineligible for adjuvant olaparib because she is negative for a germline BRCA mutation.

Abemaciclib vs robiciclib

win robiciclib because Abemaciclib Has 83,5% of monarche participants happened a underlying bowel comorbidity and Diarrea is common with abemaciclib

[arrangoiz]

Monaleesa-3 Trial in Metastatic Breast Cancer

The CDK 4/6 inhibitors are a class of oral drugs that have been approved for HR+, HER2-negative metastatic breast cancer in the first-line setting or after progression on prior aromatase inhibitor In the MONALEESA-3 trial: Ribociclib in combination with fulvestrant: Showed progression-free survival (20.5 months vs. 12.8 months) and overall survival benefit over fulvestrant alone in HR+,…

[stranotizie]

Novità al Congresso della Società Europea di Oncologia (European Society for Medical Oncology, ESMO), in corso a Madrid dal 20 al 24 ottobre. Novartis ha presentato gli ultimi risultati di un’analisi esplorativa per sottogruppi sulla sopravvivenza libera da malattia invasiva (iDFS) dello studio registrativo di fase III NATALEE, relativo all’impiego di ribociclib nel tumore alla mammella in fase iniziale HR+/HER2- Dopo 27,7 mesi di follow-up, i benefici di iDFS con ribociclib in aggiunta alla terapia endocrina (ET) sono coerenti tra tutti i sottogruppi chiave, in comparazione con la sola terapia endocrina, in pazienti con tumore alla mammella in fase iniziale in stadio II e III, positivo per i recettori ormonali e negativo per il recettore 2 del fattore umano di crescita epidermica (HR+/HER2-). I risultati sono coerenti con quelli della popolazione complessiva dello studio, a conferma del fatto che il beneficio non è determinato da uno specifico sottogruppo di pazienti. “Le analisi per sottogruppi forniscono un quadro più completo dei benefici clinici per i pazienti e sono cruciali per guidare le scelte di trattamento, perché aiutano a capire come diversi sottogruppi possono rispondere alle terapie,” commenta Aditya Bardia, Attending Physician, Medical Oncology, Mass General Cancer Center e Professore Associato di Medicina all’Harvard Medical School, membro del team di ricerca dello studio NATALEE, “Considerati i risultati dei pazienti trattati con la sola terapia endocrina, questa analisi evidenzia i possibili benefici di aggiungere ribociclib alla terapia endocrina per ridurre il rischio di recidive. Questi dati forniscono insight importanti su come pensiamo al rischio residuo in questa popolazione e facciamo decisioni sul trattamento adiuvante per pazienti con tumore al seno localizzato.” “Anche con la terapia endocrina le recidive del tumore rimangono poco prevedibili, e troppi pazienti diagnosticati con tumore della mammella in fase iniziale in stadio II e III HR+/HER2- si trovano ad affrontare questa situazione – sottolinea Paola Coco, CSO & Medical Affairs Head, Novartis Italia – Siamo orgogliosi di fornire con questi dati una risposta alla necessità di una nuova opzione adiuvante che riduca il rischio di recidive in maniera coerente tra i diversi gruppi di pazienti a rischio”. È in corso un’ulteriore analisi dello studio NATALEE. Altri dati, tra cui l’analisi finale di efficacia dello studio NATALEE, saranno condivisi nelle prossime occasioni di incontri medici.   Lo studio NATALEE NATALEE è uno studio globale multicentrico di Fase III randomizzato, in aperto, per la valutazione dell’efficacia e della sicurezza di ribociclib con terapia endocrina come trattamento adiuvante rispetto alla sola terapia endocrina nei pazienti con tumore della mammella in fase iniziale HR+/HER2-, condotto in collaborazione con TRIO. La terapia endocrina adiuvante in entrambi i bracci era un inibitore dell’aromatasi non steroideo (FANS; anastrozolo o letrozolo) e goserelin, se possibile. L’endpoint primario di NATALEE è la sopravvivenza libera da malattia invasiva (iDFS) secondo la definizione dei criteri Standardized Definitions for Efficacy End Points (STEEP). Nello studio sono stati randomizzati 5.101 pazienti adulti con tumore della mammella in fase iniziale HR+/HER2- di 20 Paesi.   Ribociclib Ribociclib ha dimostrato costantemente un beneficio in termini di OS, preservando o migliorando la qualità di vita in tre studi di Fase III nel tumore al seno metastatico. L’aggiornamento delle Linee Guida NCCN per il tumore del seno, pubblicato a gennaio 2023, raccomanda ribociclib come unico inibitore CDK4/6 di categoria 1 preferito per il trattamento di prima linea dei pazienti con tumore della mammella metastatico HR+/HER2- in combinazione con un inibitore dell’aromatasi (AI). Il farmaco è approvato in 99 Paesi, dalla FDA e dalla Commissione Europea. Negli Stati Uniti ribociclib è approvato per il trattamento dei pazienti adulti con tumore della mammella avanzato o metastatico HR+/HER2- in combinazione con un inibitore dell’aromatasi come terapia endocrina iniziale o fulvestrant come terapia endocrina iniziale o a seguito di progressione di malattia durante la terapia endocrina nelle donne in post-menopausa o negli uomini. Nell’Unione Europea ribociclib è approvato per il trattamento delle pazienti con tumore della mammella avanzato o metastatico HR+/HER2- in combinazione con un inibitore dell’aromatasi o fulvestrant come terapia endocrina iniziale o in seguito a progressione di malattia. Nelle donne in peri- o pre-menopausa, la terapia endocrina dovrebbe essere combinata con un agonista dell’ormone di rilascio dell’ormone luteinizzante. L’impegno di Novartis Novartis è impegnata a continuare lo studio di ribociclib nel tumore della mammella. La pharma svizzera sta collaborando con SOLTI, che sta conducendo lo studio clinico HARMONIA per verificare se ribociclib cambia la biologia del tumore per consentire una migliore risposta all’ET rispetto a palbociclib nei pazienti con carcinoma mammario HR+/HER2- o il sottotipo arricchito in HER223, e con l’Akershus University Hospital in Norvegia nello studio di Fase II neoadiuvante NEOLETRIB che analizza gli effetti di ribociclib nel tumore della mammella in fase iniziale HR+/HER2- per indagare il meccanismo d’azione sottostante, potenzialmente unico2 Ribociclib è stato sviluppato da Novartis Institutes for BioMedical Research (NIBR) attraverso una collaborazione di ricerca con Astex Pharmaceuticals. Fonte

[glcarissa]

Follow my Stage 4 Metastatic Breast Cancer journey on IG: @metastaticbreastcancer4

Abstract Artist with Stage 4 Breast Cancer: They say an artist becomes famous after they ...

[melonglobalcare]

Advances in the Treatment of Metastatic Breast Cancer: Paving the Way for Improved Outcomes

Metastatic breast cancer, also known as stage IV breast cancer, refers to the advanced stage of breast cancer where the disease has spread beyond the breast and nearby lymph nodes to distant organs, such as the liver, lungs, bones, or brain. It presents significant challenges to patients and healthcare professionals due to its aggressive nature and limited treatment options. However, recent years have witnessed remarkable advancements in the understanding and management of metastatic breast cancer, offering renewed hope and improved outcomes for patients.

SYMPTOMS OF METASTATIC BREAST CANCER

Understanding these symptoms can lead to timely medical evaluation and potentially improved treatment outcomes.

Persistent Fatigue: Fatigue is a common symptom experienced by many cancer patients, including those with metastatic breast cancer. However, the fatigue associated with metastatic breast cancer is often more severe and long-lasting compared to general tiredness. It may not be relieved by rest or sleep and can significantly impact daily activities and quality of life.

Bone Pain and Fractures: Metastases to the bones occur in a substantial number of individuals with metastatic breast cancer. Bone metastases can lead to localized pain, often in the spine, hips, ribs, or long bones of the arms and legs. The pain can be persistent, worsening over time, and may be accompanied by fractures or increased susceptibility to fractures.

Shortness of Breath and Chest Pain: When metastatic breast cancer spreads to the lungs, it can cause respiratory symptoms such as shortness of breath, wheezing, or a persistent cough. Additionally, chest pain or discomfort may be experienced due to the involvement of the chest wall or nearby lymph nodes.

4. Abdominal or Digestive Issues: Metastases to the liver or abdominal organs can cause a range of symptoms, including abdominal pain or discomfort, bloating, changes in bowel habits, loss of appetite, nausea, vomiting, or unexplained weight loss. Jaundice, indicated by yellowing of the skin and eyes, may also occur if the liver is affected

It is important to note that the symptoms of metastatic breast cancer can be similar to those of other conditions, and not all individuals will experience the same symptoms. However, if you notice any persistent or concerning changes in your body, it is crucial to consult a healthcare professional for further evaluation.

Early detection of metastatic breast cancer can lead to timely interventions, including targeted therapies, palliative care, and support services, which may improve quality of life and potentially extend survival. Regular self-examinations, routine mammograms, and ongoing communication with your healthcare provider are essential for staying vigilant and catching any potential signs of metastatic breast cancer at the earliest possible stage.

TREATMENT OPTIONS FOR METASTATIC BREAST CANCER

Precision Medicine and Targeted Therapies: The advent of precision medicine has revolutionized the treatment landscape for metastatic breast cancer. Extensive research has unraveled the complex molecular and genetic makeup of breast cancer tumors, leading to the development of targeted therapies that aim to exploit specific abnormalities driving cancer growth. Drugs like trastuzumab and pertuzumab have dramatically improved outcomes for patients with HER2-positive metastatic breast cancer, while CDK4/6 inhibitors, such as palbociclib and ribociclib, have shown impressive results in hormone receptor-positive breast cancer.

Immunotherapy: Immunotherapy, an innovative approach that harnesses the body’s immune system to fight cancer cells, has emerged as a promising treatment option for metastatic breast cancer. Immune checkpoint inhibitors, such as pembrolizumab and atezolizumab, have shown encouraging results in a subset of patients with triple-negative breast cancer (TNBC), a particularly aggressive subtype with limited treatment options. Ongoing clinical trials are further exploring the potential of immunotherapy in combination with other treatments to enhance efficacy.

Advancements in Chemotherapy: While chemotherapy remains a cornerstone in the management of metastatic breast cancer, advancements in this field have improved both efficacy and tolerability. Novel chemotherapeutic agents, such as nab-paclitaxel, have demonstrated improved response rates and reduced side effects. Additionally, the development of liposomal formulations has allowed for more targeted delivery of chemotherapy, minimizing damage to healthy cells and optimizing treatment outcomes.

Liquid Biopsies and Molecular Profiling: The utilization of liquid biopsies and molecular profiling has transformed the way metastatic breast cancer is diagnosed and treated. Liquid biopsies enable the analysis of circulating tumor cells and cell-free DNA, providing real-time information about the tumor’s genetic profile and allowing for more personalized treatment decisions. Molecular profiling helps identify potential therapeutic targets and predict treatment response, enabling oncologists to tailor therapy to each patient’s specific tumor characteristics.

Supportive Care and Patient Empowerment: Recognizing the multifaceted impact of metastatic breast cancer on patients’ lives, healthcare professionals are increasingly emphasizing the importance of supportive care services. Palliative care, pain management, psychological support, and access to support groups are essential components of comprehensive cancer care, improving patients’ quality of life and emotional well-being. Moreover, patient empowerment programs equip individuals with knowledge and resources to actively participate in their treatment decisions, fostering a sense of control and engagement throughout their cancer journey.

Medicines can also play a big role in the process of killing the cancer cells. You can buy the anti-cancer drug online Ramiven 150mg Tablets is used to treat Metastatic Breast Cancer. It helps the immune system to fight against the cancer cells. This medicine is supplied online by Melon GlobalCare. Melon GlobalCare is a well-established healthcare brand and one of the world’s upcoming distributors in the pharmaceutical industry. They offer the finest Medical Facilities and provide the highest quality medications at reasonable prices.

[life-with-cancer]

Uma coisa que percebi nesses 4 meses a tomar medicação para o câncer (zoladex, letrozol e ribociclib) é que fiquei mais sensível a tudo.

Sensível ao sol, a remédios, óleos essenciais, comida, enfim… tudo. Mais emotiva também… com as emoções a flor da pele.

É fato que muita coisa em nós é mesmo hormônios. E esse medicação induz a menopausa. De forma bem agressiva, removendo o estrogênio do corpo.

A pele ficou super seca, o cabelo cai demais… além de ter ficado super fino.

Enfim, é literalmente descobrir uma nova forma de viver… de comer… de se cuidar.

Uma menopausa forçada aos 36 anos impacta a mente de qualquer pessoa.

[munaeem]

Breast cancer: ribociclib reduces the risk of recurrence by 25%

Breast cancer is the second most common cancer in women worldwide and is responsible for a significant number of deaths. Hormone receptor-positive, HER2-negative advanced breast cancer is one of the most common subtypes of breast cancer and is typically treated with a combination of hormone therapy and chemotherapy. However, despite the advances in breast cancer treatment, many patients still…